A Phase 1 interventional study of MEDI-551 in Blood Cancer and Advanced B Cell Malignancies, sponsored by AstraZeneca. Completed at 3 sites in Japan. Open to participants aged 20 Years to 130 Years. Per ClinicalTrials.gov, last updated 2017-06-12.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Hematologic Neoplasms with a site in Japan — 5 open to participants now, 6 under way, 1 of them phase 3. Hematologic Neoplasms · Japan.
Among the 19 studies in Hematologic Neoplasms with a site in Japan, this one is the 14th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2011, is one of 7 in phase 1, and was the 7th registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.
Browse Hematologic Neoplasms studies →5 of the 19 studies in Hematologic Neoplasms with a site in Japan are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Japan, United States, France and 1 more country
Ages 18+
Swedish Orphan Biovitrum · Sites in Japan, United States, Canada and 5 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Japan, United States, Belgium and 8 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Japan, United States, Argentina and 48 more countries
Ages 18+
Kite, A Gilead Company · Sites in Japan, United States, Australia and 11 more countries
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 20 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 5
First in 2006; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 96 across the 18 interventional studies, 1,500 across the 1 observational. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 5 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Hematologic Neoplasms with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06782373Swedish Orphan BiovitrumA Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | 2026-12-30 |
| NCT04634552Janssen Research & Development, LLCA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Hematologic Neoplasms with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability of MEDI-551 in Japanese patients with relapsed or refractory advanced B-cell malignancies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MEDI-551
MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
Number of Participants With Adverse Events
Time frame: From baseline to 30 days after the last dose of study drug
Number of Participants With Dose Limiting Toxicities
A MEDI-551 treatment-related AE of any toxicity grade that lead to an inability to receive a full cycle (2 doses) of MEDI-551, or, any Grade 3 or higher toxicity that could not be reasonably ascribed to another cause, such as disease progression or accident.
Time frame: From baseline to 28 days after the first dose of study drug
Maximum Tolerated Dose
A dose was considered non-tolerated and dose escalation stopped if ≥2 of up to 6 evaluable patients experienced a DLT at any dose level. MTD is the last dose level before the non-tolerated dose.
Time frame: From baseline to 28 days after the first dose of study drug
MEDI-551 Trough Concentration Levels at Day 0 (Pre-dose)
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
Time frame: Day 0 (pre-dose)
MEDI-551 Trough Concentration Levels at Day 7
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
Time frame: Day 7
MEDI-551 Trough Concentration Levels at Day 28
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
Time frame: Day 28
MEDI-551 Trough Concentration Levels at Day 56
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
Time frame: Day 56
MEDI-551 Trough Concentration Levels at Day84
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
Time frame: Day 84
MEDI-551 Trough Concentration Levels at Day 112
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
Time frame: Day 112
MEDI-551 Trough Concentration Levels at Day 140
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
Time frame: Day 140
MEDI-551 Trough Concentration Levels at Day 168
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
Time frame: Day 168
Anti-MEDI-551 Antibodies
Only 1 patient was tested positive for ADA at pre-dose of Cycle 1 Day 1. However, it was considered as false-positive because the titer value was close to the cut point, and this patient was tested negative for ADA at all subsequent cycles post-baseline.
Time frame: From baseline to 30 days after the last dose of study drug
Number of Participants With Tumour Response in FL Patients
Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007). CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative. PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.
Time frame: From the baseline to 30 days after the last dose of study drug
Number of Participants With Tumour Response in DLBCL Patients
Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007). CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative. PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.
Time frame: From the baseline to 30 days after the last dose of study drug
Number of Participants With Tumour Response in CLL Patients
Tumour response is defined as complete remission (CR) or partial remission (PR) (Hallek M et al 2008). CR: all of the following criteria have to be met, and patients have to lack disease-related constitutional symptoms; Lymphadenopathy: None; Hepatomegaly: None; Splenomegaly: None; Blood lymphocytes: \<4000/μL; Marrow: Normocellular, \<30%lymphocytes, no B-lymphoid nodules, hypocellular marrow defines CR with incomplete marrow recovery; Platelet count: \>100000/μL; Hemoglobin: \>11.0 g/dL; Neutrophils: \>1500/μL PR: at least 2 of the criteria of group A plus 1 of the criteria of group B have to be met. Group A: Lymphadenopathy: Decrease ≥50%; Hepatomegaly: Decrease ≥50%; Splenomegaly: Decrease ≥50%; Blood lymphocytes: Decrease ≥50% from baseline; Marrow: 50% reduction in marrow infiltrate, or B-lymphoid nodules. Group B: Platelet count: 100000/μL or increase ≥50% over baseline; Hemoglobin: \>11.0 g/dL or increase ≥50% over baseline; Neutrophils: \>1500/μL or \>50% improvement over baseline.
Time frame: From the baseline to 30 days after the last dose of study drug
Number of Participants With Tumour Response in MM Patients
Tumour response is defined as complete response (CR) or partial response (PR) (Durie M et al 2006). CR: Negative immunofixation on the serum and urine, and Disappearance of any soft tissue plasmacytomas and 5% or less plasma cells in bone marrow PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \<200mg per 24 h. If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥30%. In addition to the above listed criteria, if present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is also required.
Time frame: From the baseline to30 days after the last dose of study drug
First patient enrolled on 25 May 2011. Last patient last visit on 15 September 2015.
| Milestone | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| Started | 3 | 7 | 4 | 6 |
| Completed | 3 | 6 | 2 | 6 |
| Not completed | 0 | 1 | 2 | 0 |
| Withdrew: Withdrawal of concent | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 2 | 0 |
| Participants | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| At least 1 Adverse Events (AE) | 3 | 6 | 4 | 6 |
| At least 1 AE of CTCAE Grade 3 or higher | 2 | 2 | 1 | 3 |
| At least 1 Serious Adverse Events (SAE) | 1 | 0 | 0 | 0 |
A MEDI-551 treatment-related AE of any toxicity grade that lead to an inability to receive a full cycle (2 doses) of MEDI-551, or, any Grade 3 or higher toxicity that could not be reasonably ascribed to another cause, such as disease progression or accident.
| Participants | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| At least 1 Dose Limiting Toxicity | 0 | 1 | 0 | 2 |
| CTCAE Grade 3 or higher non-hematologic toxicity | 0 | 1 | 0 | 1 |
| CTCAE Grade 3 or higher hematologic toxicity | 0 | 0 | 0 | 1 |
A dose was considered non-tolerated and dose escalation stopped if ≥2 of up to 6 evaluable patients experienced a DLT at any dose level. MTD is the last dose level before the non-tolerated dose.
| mg/kg | MEDI-551 |
|---|---|
| Maximum Tolerated Dose | 8 |
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
| μg/mL | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| MEDI-551 Trough Concentration Levels at Day 0 (Pre-dose) | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
| μg/mL | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| MEDI-551 Trough Concentration Levels at Day 7 | 21.3 ± 8.65 | 39.2 ± 9.13 | 91.9 ± 31.1 | 104 ± 29.0 |
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
| μg/mL | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| MEDI-551 Trough Concentration Levels at Day 28 | 23.2 ± 5.82 | 36.2 ± 5.34 | 103 ± 29.0 | 115 ± 21.3 |
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
| μg/mL | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| MEDI-551 Trough Concentration Levels at Day 56 | 22.0 ± 4.92 | 33.2 ± 6.92 | 89.5 ± 13.9 | 114 ± 33.1 |
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
| μg/mL | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| MEDI-551 Trough Concentration Levels at Day84 | 21.7 ± 4.40 | 33.7 ± 4.24 | 91.6 ± 9.25 | 103 ± 26.3 |
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
| μg/mL | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| MEDI-551 Trough Concentration Levels at Day 112 | 22.9 ± 3.10 | 35.3 ± 5.07 | 85.5 ± NA | 114 ± 64.4 |
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
| μg/mL | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| MEDI-551 Trough Concentration Levels at Day 140 | 22.1 ± NA | 36.3 ± 10.5 | 86.1 ± NA | 117 ± 62.0 |
Lower limit of quantification for MEDI-551 was 0.1 μg/mL.
| μg/mL | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| MEDI-551 Trough Concentration Levels at Day 168 | 20.0 ± NA | 31.4 ± 8.30 | 94.1 ± NA | 82.1 ± NA |
Only 1 patient was tested positive for ADA at pre-dose of Cycle 1 Day 1. However, it was considered as false-positive because the titer value was close to the cut point, and this patient was tested negative for ADA at all subsequent cycles post-baseline.
| Participants | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| positive at least 1 time point | 0 | 0 | 1 | 0 |
| negative at all time points | 3 | 7 | 3 | 6 |
Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007). CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative. PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.
| Participants | 2 mg/kg (FL) | 4 mg/kg (FL) | 8 mg/kg (FL) | 12 mg/kg (FL) |
|---|---|---|---|---|
| Number of Participants With Tumour Response in FL Patients | 2 | 3 | 2 | 2 |
Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007). CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative. PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.
| Participants | 2 mg/kg (DLBCL) | 4 mg/kg (DLBCL) | 8 mg/kg (DLBCL) | 12 mg/kg (DLBCL) |
|---|---|---|---|---|
| Number of Participants With Tumour Response in DLBCL Patients | — | 0 | 1 | 2 |
Tumour response is defined as complete remission (CR) or partial remission (PR) (Hallek M et al 2008). CR: all of the following criteria have to be met, and patients have to lack disease-related constitutional symptoms; Lymphadenopathy: None; Hepatomegaly: None; Splenomegaly: None; Blood lymphocytes: \<4000/μL; Marrow: Normocellular, \<30%lymphocytes, no B-lymphoid nodules, hypocellular marrow defines CR with incomplete marrow recovery; Platelet count: \>100000/μL; Hemoglobin: \>11.0 g/dL; Neutrophils: \>1500/μL PR: at least 2 of the criteria of group A plus 1 of the criteria of group B have to be met. Group A: Lymphadenopathy: Decrease ≥50%; Hepatomegaly: Decrease ≥50%; Splenomegaly: Decrease ≥50%; Blood lymphocytes: Decrease ≥50% from baseline; Marrow: 50% reduction in marrow infiltrate, or B-lymphoid nodules. Group B: Platelet count: 100000/μL or increase ≥50% over baseline; Hemoglobin: \>11.0 g/dL or increase ≥50% over baseline; Neutrophils: \>1500/μL or \>50% improvement over baseline.
| Participants | 2 mg/kg (CLL) | 4 mg/kg (CLL) | 8 mg/kg (CLL) | 12 mg/kg (CLL) |
|---|---|---|---|---|
| Number of Participants With Tumour Response in CLL Patients | 1 | — | — | 0 |
Tumour response is defined as complete response (CR) or partial response (PR) (Durie M et al 2006). CR: Negative immunofixation on the serum and urine, and Disappearance of any soft tissue plasmacytomas and 5% or less plasma cells in bone marrow PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \<200mg per 24 h. If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥30%. In addition to the above listed criteria, if present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is also required.
| Participants | 2 mg/kg (MM) | 4 mg/kg (MM) | 8 mg/kg (MM) | 12 mg/kg (MM) |
|---|---|---|---|---|
| Number of Participants With Tumour Response in MM Patients | — | 0 | — | — |
Collected over AEs were collected throughout the study, from informed consent until the end of 30 days after study treatment. The follow-up period is defined as 3 months after study treatment is discontinued.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2 mg/kg | — | 1/3 (33.3%) | 3/3 (100%) |
| 4 mg/kg | — | 0/7 (0%) | 6/7 (85.7%) |
| 8 mg/kg | — | 0/4 (0%) | 4/4 (100%) |
| 12 mg/kg | — | 0/6 (0%) | 6/6 (100%) |
| Event | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| EpiglottitisInfections and infestations | 1/3 | 0/7 | 0/4 | 0/6 |
| Event | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg |
|---|---|---|---|---|
| HypertriglyceridaemiaMetabolism and nutrition disorders | 1/3 | 1/7 | 4/4 | 0/6 |
| Infusion related reactionInjury, poisoning and procedural complications | 2/3 | 1/7 | 3/4 | 3/6 |
| White blood cell count decreasedInvestigations | 2/3 | 2/7 | 0/4 | 0/6 |
| Lymphocyte count decreasedInvestigations | 1/3 | 2/7 | 0/4 | 0/6 |
| Neutrophil count decreasedInvestigations | 1/3 | 2/7 | 0/4 | 0/6 |
| Aspartate aminotransferase increasedInvestigations | 1/3 | 0/7 | 0/4 | 0/6 |
| Blood lactate dehydrogenase increasedInvestigations | 1/3 | 0/7 | 0/4 | 0/6 |
| Blood triglycerides increasedInvestigations | 1/3 | 0/7 | 0/4 | 0/6 |
| NasopharyngitisInfections and infestations | 1/3 | 0/7 | 1/4 | 1/6 |
| Upper respiratory tract infectionInfections and infestations | 1/3 | 0/7 | 0/4 | 1/6 |
All patients who received at least 1 dose of MEDI-551.
| Age, Continuous(Years) | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg | Total |
|---|---|---|---|---|---|
| Mean | 50.3 ± 8.1 | 57.4 ± 10.5 | 67.0 ± 8.7 | 67.3 ± 11.4 | 61.3 ± 11.4 |
| Sex: Female, Male(Participants) | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg | Total |
|---|---|---|---|---|---|
| Female | 2 | 5 | 0 | 3 | 10 |
| Male | 1 | 2 | 4 | 3 | 10 |
| Disease Type(Participants) | 2 mg/kg | 4 mg/kg | 8 mg/kg | 12 mg/kg | Total |
|---|---|---|---|---|---|
| CLL | 1 | 0 | 0 | 1 | 2 |
| DLBCL | 0 | 2 | 2 | 2 | 6 |
| FL | 2 | 4 | 2 | 3 | 11 |
| MM | 0 | 1 | 0 | 0 | 1 |
Ran from May 2011 to primary completion in Sep 2015, 51 months.
Results were first posted in Apr 2017, 1 year 6 months after primary completion.
Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's 51 months is above that.
Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inebilizumab